X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with AANJANEYA LIFECARE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs DR. DATSONS LABS - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA DR. DATSONS LABS AJANTA PHARMA/
DR. DATSONS LABS
 
P/E (TTM) x 25.4 -10.9 - View Chart
P/BV x 10.5 0.2 6,445.8% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 AJANTA PHARMA   DR. DATSONS LABS
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
DR. DATSONS LABS
Mar-14
AJANTA PHARMA/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs1,720126 1,369.4%   
Low Rs1,10331 3,569.6%   
Sales per share (Unadj.) Rs194.6133.0 146.3%  
Earnings per share (Unadj.) Rs45.20.2 29,825.8%  
Cash flow per share (Unadj.) Rs50.36.6 761.2%  
Dividends per share (Unadj.) Rs8.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs132.0128.8 102.5%  
Shares outstanding (eoy) m88.7731.66 280.4%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x7.30.6 1,232.7%   
Avg P/E ratio x31.2516.1 6.0%  
P/CF ratio (eoy) x28.111.8 237.0%  
Price / Book Value ratio x10.70.6 1,759.5%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m125,2992,477 5,057.7%   
No. of employees `000NANA-   
Total wages/salary Rs m2,57056 4,589.1%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m17,2754,211 410.3%  
Other income Rs m16679 211.3%   
Total revenues Rs m17,4424,289 406.6%   
Gross profit Rs m5,807569 1,021.3%  
Depreciation Rs m451204 220.5%   
Interest Rs m49430 11.4%   
Profit before tax Rs m5,47413 43,102.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4606 23,932.8%   
Profit after tax Rs m4,0145 83,627.1%  
Gross profit margin %33.613.5 248.9%  
Effective tax rate %26.748.0 55.5%   
Net profit margin %23.20.1 20,382.4%  
BALANCE SHEET DATA
Current assets Rs m7,6396,852 111.5%   
Current liabilities Rs m2,7156,711 40.5%   
Net working cap to sales %28.53.3 851.2%  
Current ratio x2.81.0 275.6%  
Inventory Days Days43161 26.9%  
Debtors Days Days79318 24.7%  
Net fixed assets Rs m6,9143,673 188.2%   
Share capital Rs m177317 55.9%   
"Free" reserves Rs m11,4423,761 304.2%   
Net worth Rs m11,7214,078 287.4%   
Long term debt Rs m1491,671 8.9%   
Total assets Rs m14,81412,633 117.3%  
Interest coverage x112.91.0 10,970.4%   
Debt to equity ratio x00.4 3.1%  
Sales to assets ratio x1.20.3 349.9%   
Return on assets %27.43.4 796.5%  
Return on equity %34.20.1 29,093.2%  
Return on capital %46.57.7 606.4%  
Exports to sales %55.122.9 240.9%   
Imports to sales %6.014.3 42.0%   
Exports (fob) Rs m9,527964 988.3%   
Imports (cif) Rs m1,038602 172.4%   
Fx inflow Rs m10,422964 1,081.1%   
Fx outflow Rs m1,678607 276.4%   
Net fx Rs m8,744357 2,449.9%   
CASH FLOW
From Operations Rs m3,2641,345 242.7%  
From Investments Rs m-2,093-2,256 92.8%  
From Financial Activity Rs m-1,186-1,200 98.8%  
Net Cashflow Rs m-15-2,111 0.7%  

Share Holding

Indian Promoters % 73.8 4.5 1,629.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 0.0 -  
FIIs % 7.6 1.4 563.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 94.1 18.1%  
Shareholders   20,968 20,807 100.8%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   PANACEA BIOTECH  DISHMAN PHARMA  J.B.CHEMICALS  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 16, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS